We use technology to improve diagnostic and treatment accuracy for patients. We develop state of the art solutions to improve clinical outcome, and hence improve quality of life.
Overview
Biobot Surgical Pte Ltd aims to be a global technology leader in minimally-invasive robotic healthcare solutions.
Our Company
Biobot Surgical Pte Ltd was incorporated in 2007 in Singapore, and became a member of ZIG Venture since 2011.
To ensure success, a team of talents has been put together in the areas of robotic design and technology, medical image processing, software development and clinical application.
To date, the iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), U.S.A (US FDA), Australia (TGA) and Singapore (HSA) and is being used in some of the most prestigious hospitals around the world.
Striving to become the gold standard in diagnosis and prognosis of prostate cancer, the Mona Lisa’s development has been a process of evolution and is the latest in our state of the art new generation designs.
News
May 9, 2022
医疗器械创新网
We are proud to share that our iSR’obot Mona Lisa is the first robotic assisted prostate fusion biopsy system to complete a multi-center clinical trial in China.
During the multi center trial, the Mona Lisa system proved reliable, safe and easy to use, and achieved superior outcomes to conventional methods without robotics assistance.
This paves the way for NMPA submission and great momentum has now been forged for the Mona Lisa globally in addition to the recent FDA clearance of the Mona Lisa 2.0 in Dec 2021.
This further validates our dedication to producing the Best in Class Robotics Assisted Transperineal Solutions for Prostate Cancer. After all, patients deserve no less.
March 11, 2022
PR Newswire
Biobot Surgical, a robotic-assisted percutaneous surgical systems company, is delighted to announce a MOU with BEBIG Medical, a global provider of radiotherapy products and a brachytherapy leader based in Europe to work together to provide a robotic-guided high dose rate (HDR) brachytherapy solution for prostate cancer treatment.
Biobot Surgical developed the iSR’obot Mona Lisa 2.0, a robotic-assisted percutaneous surgical system that allows clinicians to plan and position needles during image-guided diagnostic and interventional prostate procedures.
Globally, prostate cancer is the second most common cancer diagnosed in men and fourth most common cancer overall [1]. The treatment options depends on factors such as the stage of the cancer, the patient’s overall health, and the benefits and side effects of the treatment option. HDR brachytherapy is a form of radiotherapy which involves a thin tube inserted into the prostate gland and a radiation source is then passed through the tube to kill the cancer cells. Traditionally, the ultrasound-guided HDR brachytherapy procedure uses a template grid for needle insertion into the prostate.
Using the iSR’obot Mona Lisa 2.0 for HDR brachytherapy, it automatically guides the needle insertion by a clinician to within 1.0mm* accuracy of the targeted needle position for treatment. The robotic arm allows flexibility of angulated needle trajectory for an optimal treatment plan and avoids critical anatomical structures.
“BEBIG Medical is a well established brand in brachytherapy, while Biobot Surgical is known for its accurate placement of needles. The partnership enables our companies to bring robotic-assisted brachytherapy solutions to patients.” said Mr. Sim Kok Hwee, CEO of Biobot Surgical.
“The future trend of medical device technology was moving toward digitalization, automation and artificial intelligence. The joint partnership is a vivid display of these orientations to achieve clinical excellence.” said Mr. George Chan, Chairman and CEO of BEBIG Medical.
The iSR’obot Mona Lisa 2.0 has been U.S. FDA 510(k) cleared and is expected to obtain EU MDR approval in 2023. Its first-generation iSR’obot Mona Lisa is marketed in Europe, Australia, and Asia. Clinical studies have demonstrated that iSR’obot Mona Lisa has a clinically significant prostate cancer detection rate of 81 percent higher than cognitive fusion biopsy. Clinical data also shows that the transperineal, dual-cone needle trajectory technology minimizes infection complications [2,3,4,5].
About Biobot Surgical Pte. Ltd.
Biobot Surgical is headquartered in Singapore and focuses on robotics-assisted percutaneous surgical systems. The company is expanding its core technology in precision needle positioning to address comprehensive prostate cancer care to improve patient prostate cancer outcomes.
About BEBIG Medical GmbH
BEBIG Medical GmbH (“BEBIG Medical”) is a global provider of high quality radiation therapy products for cancer treatment headquartered in Berlin, Germany. Preceded by the high dose brachytherapy business unit of Eckert & Ziegler AG, BEBIG Medical has a heritage of more than 40 years’ experience in brachytherapy field and continues to provide affordable healthcare with proven clinical outcomes via strong and viable technology.BEBIG Medical’s US subsidiary, Mick Radio-Nuclear Instruments, Inc., is also known internationally for its manufacturing expertise in the field of applicators and accessories to advance brachytherapy. With a team of professionals and offices in Europe, United States and Asia, the company is empowered to serve customers in more than 65 countries and regions together with a worldwide distribution network.
*based on internal bench test
March 6, 2022
PR Newswire
SINGAPORE, March 5, 2022 /PRNewswire/ — Biobot Surgical is excited to announce U.S. FDA 510(k) clearance of the iSR’obot Mona Lisa 2.0. The new robotic assisted transperineal needle-guidance system allows urologists to plan and position a single needle or multiple needles during image-guided diagnostic and interventional prostate procedures.
The iSR’obot Mona Lisa 2.0 is the latest addition to Biobot Surgical’s iSR’obot Mona Lisa product portfolio. “The Mona Lisa system was conceptualized and engineered to position biopsy or treatment needles transperineally. The advantages of transperineal procedures are lower infection rates and better coverage of the anterior zone compared to transrectal procedures. In addition, most ablation procedures are also carried out transperineally. The Mona Lisa system simplifies needle positioning by providing robotic assisted guidance for the insertion.” said Sim Kok Hwee, CEO of Biobot Surgical.
The iSR’obot Mona Lisa 2.0 automatically supports needle positioning during transperineal prostate biopsy and prostate cancer ablation based on a customized needle plan.
The new features include:
- A detachable needle guide that holds a biopsy needle or multiple ablation needles
- Visualization and planning of the needle locations for a prostate cancer ablation procedure
- Ability to re-adjust a target location when the needle deflects
The second-generation iSR’obot Mona Lisa system retains the MR-ultrasound image-fusion prostate biopsy technology. The robotic system’s proprietary dual-cone needle trajectory technology enables the extraction of multiple biopsy cores through the same needle entry points. The first-generation iSR’obot Mona Lisa is marketed in Europe, Australia, and Asia. Clinical studies have demonstrated that iSR’obot Mona Lisa has a clinically significant prostate cancer detection rate of 81 percent higher than cognitive fusion biopsy. Clinical data also shows that the transperineal, dual-cone needle trajectory technology minimizes infection complications[1-4].
Biobot Surgical Pte. Ltd is headquartered in Singapore and focuses on medical robotics solutions. The company is expanding its core technology in precision needle positioning to address comprehensive prostate cancer care to improve patient prostate cancer outcomes.
For more information: https://biobotsurgical.com/
References:
1. Mischinger, J., Kaufmann, S., Russo, G. I., Harland, N., Rausch, S., Amend, B., Scharpf, M., Loewe, L., Todenhoefer, T., Notohamiprodjo, M., Nikolaou, K., Stenzl, A., Bedke, J., & Kruck, S. (2018). Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy. BJU international, 121(5), 791–798. https://doi.org/10.1111/bju.14089
2. Miah, S., Servian, P., Patel, A., Lovegrove, C., Skelton, L., Shah, T. T., Eldred-Evans, D., Arya, M., Tam, H., Ahmed, H. U., & Winkler, M. (2020). A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach. Journal of robotic surgery, 14(1), 69–74. https://doi.org/10.1007/s11701-019-00929-y
3. Zhang, K., Zhang, Z., Liu, M., Zhu, G., & Roobol, M. J. (2020). Comparison of clinically significant prostate cancer detection by MRI cognitive biopsy and in-bore MRI-targeted biopsy for naïve biopsy patients. Translational andrology and urology, 9(2), 243–249. https://doi.org/10.21037/tau.2020.02.20
4. Valerio, M., Donaldson, I., Emberton, M., Ehdaie, B., Hadaschik, B. A., Marks, L. S., Mozer, P., Rastinehad, A. R., & Ahmed, H. U. (2015). Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. European urology, 68(1), 8–19. https://doi.org/10.1016/j.eururo.2014.10.026
April 20, 2021
We have an opening for ZIG Innovation Fellowship Program!
Since March 2021, ZIG Ventures has been appointed a partner under the Enterprise Singapore Innovation and Enterprise Fellowship (IFP) Programme. There is an opening for ZIG Innovation Fellowship Program.
ZIG Ventures is a venture investment and commercialization company that focuses on investing into healthcare biomedical technologies companies and proactively develops these companies by working side by side with the founders, building key capabilities and driving commercialization through its global key opinion and distributorship networks.
Biobot Surgical is a member of ZIG Ventures.
Click on this post to find out more about the program!
October 15, 2019
4th Myanmar Nephro-Urology Society Conference
We are proud to share our debut showcase in Myanmar at the 4th Myanmar Nephro-Urology Society Conference held over the weekend on 12-13 Oct 2019.